Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
This marks the second indication for which gumokimab has gained NDA review acceptance
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The accelerated review covers WCK 5222 for multiple critical infections
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
